Premium Nahrungsergänzungsmittel | artgerecht

Papillary Thyroid Carcinoma – Causes and Treatment

Papillary thyroid carcinoma is the most common type of thyroid cancer. It grows slowly and carries an excellent prognosis when diagnosed and treated early.

Regular tips about health Regular tips about health

Things worth knowing about "Papillary Thyroid Carcinoma"

Papillary thyroid carcinoma is the most common type of thyroid cancer. It grows slowly and carries an excellent prognosis when diagnosed and treated early.

What is Papillary Thyroid Carcinoma?

Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid gland, accounting for approximately 80–85% of all thyroid cancer cases. It arises from the follicular epithelial cells of the thyroid and typically grows slowly. Although PTC frequently spreads to the cervical lymph nodes, the overall prognosis remains excellent when treatment is initiated early. The 10-year survival rate exceeds 90%.

Causes and Risk Factors

The exact causes of papillary thyroid carcinoma are not fully understood. However, several risk factors have been identified:

Radiation exposure: Ionizing radiation to the head and neck region, especially during childhood, is the most well-established risk factor.
Genetic mutations: Mutations in the BRAF gene (particularly BRAF V600E) and RET/PTC rearrangements are commonly detected in tumor tissue.
Family history: A familial predisposition to thyroid cancer or certain hereditary syndromes (e.g., familial adenomatous polyposis) increases the risk.
Female sex: Women are two to three times more likely to develop PTC than men.
Dietary iodine intake: A possible association with high iodine intake has been discussed, though evidence remains inconclusive.

Symptoms

In the early stages, papillary thyroid carcinoma often causes no symptoms and is frequently discovered incidentally. When symptoms do occur, they may include:

A painless lump in the thyroid gland or neck
Enlarged lymph nodes in the neck
Difficulty swallowing or a sensation of pressure in the throat
Hoarseness due to involvement of the recurrent laryngeal nerve
Rarely: breathing difficulties in cases of advanced tumor growth

Diagnosis

Diagnosis is established through a combination of imaging studies, tissue sampling, and laboratory tests:

Imaging Studies

Thyroid ultrasound: The initial examination of choice for evaluating thyroid nodules; suspicious features include irregular margins, microcalcifications, and increased vascularity.
Thyroid scintigraphy: Assesses the functional activity of thyroid nodules.
CT or MRI: Used when local invasion or lymph node involvement is suspected.

Tissue Examination

Fine needle aspiration biopsy (FNAB): The primary preoperative diagnostic method, providing cytological assessment of thyroid nodules.
Histopathological examination: Definitive diagnosis is confirmed after surgical removal and histological analysis of the resected tissue.

Laboratory Tests

Measurement of TSH, free T3, and free T4 to assess thyroid function
Thyroglobulin as a tumor marker for monitoring disease recurrence after treatment

Treatment

Treatment depends on tumor size, extent of disease, and the individual risk profile of the patient.

Surgery

Total thyroidectomy (complete removal of the thyroid gland) is the standard surgical approach for intermediate- and high-risk cases. In very small, low-risk tumors, a hemithyroidectomy (removal of one thyroid lobe) may be sufficient. Affected lymph nodes are also removed during surgery.

Radioiodine Therapy

Following surgery, radioiodine therapy (RIT) with radioactive iodine-131 is commonly administered. It destroys any remaining thyroid tissue and potential metastatic lesions. This treatment is effective only when tumor cells retain the ability to take up iodine.

TSH Suppression Therapy

To reduce the risk of recurrence, patients take levothyroxine after surgery to suppress TSH levels, thereby inhibiting any residual tumor cell growth that may be TSH-dependent.

Targeted Therapies

In advanced or refractory cases, tyrosine kinase inhibitors such as sorafenib or lenvatinib may be used to inhibit tumor progression by blocking specific molecular signaling pathways.

Prognosis and Follow-Up

The prognosis of papillary thyroid carcinoma is among the most favorable of all cancers. Regular follow-up includes neck ultrasound, serum thyroglobulin measurements, and additional imaging studies as needed. Although recurrence is possible, it is generally manageable and rarely life-threatening.

References

Haugen BR et al. - 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016.
Schlumberger M et al. - Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. New England Journal of Medicine, 2015.
World Health Organization (WHO) - Classification of Tumours: Endocrine and Neuroendocrine Tumours, 5th Edition, 2022.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category